These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27091806)

  • 1. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
    Cousin S; Toulmonde M; Kind M; Cazeau AL; Bechade D; Coindre JM; Italiano A
    Ann Oncol; 2016 Jun; 27(6):1178-1179. PubMed ID: 27091806
    [No Abstract]   [Full Text] [Related]  

  • 2. Sarcoidosis-Like Granulomatous Reaction Associated With Pembrolizumab Immunotherapy.
    Gayá García-Manso I; García Ródenas MDM; Barroso Medel ME; Illán Gambín FJ
    Arch Bronconeumol (Engl Ed); 2018 Nov; 54(11):592-593. PubMed ID: 29801680
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.
    Martinez-Calle N; Rodriguez-Otero P; Villar S; Mejías L; Melero I; Prosper F; Marinello P; Paiva B; Idoate M; San-Miguel J
    Haematologica; 2018 Jul; 103(7):e318-e321. PubMed ID: 29650641
    [No Abstract]   [Full Text] [Related]  

  • 4. PD1 inhibitor-induced apoptotic enteropathy in the duodenum.
    Blesl A; Rainer F; Pollheimer MJ
    Gastrointest Endosc; 2019 Nov; 90(5):854-855. PubMed ID: 31260657
    [No Abstract]   [Full Text] [Related]  

  • 5. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
    Hoadley A; Sandanayake N; Long GV
    Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R; Aubin F; Roche-Kubler B; Puzenat E
    Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for classical Hodgkin's lymphoma.
    Burki TK
    Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
    Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
    Haug V; Behle V; Benoit S; Kneitz H; Schilling B; Goebeler M; Gesierich A
    Br J Dermatol; 2018 Oct; 179(4):993-994. PubMed ID: 29758087
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
    J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
    [No Abstract]   [Full Text] [Related]  

  • 12. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
    Amini-Adle M; Balme B; Dalle S
    Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO; Shapera S; Butler MO; Tsao MS
    Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract]   [Full Text] [Related]  

  • 14. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy.
    Leempoel J; Ruyssen A; Kessler R; Van Pesch V; Gille M
    Acta Neurol Belg; 2020 Apr; 120(2):451-452. PubMed ID: 31264180
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series.
    Tomelleri A; Campochiaro C; De Luca G; Cavalli G; Dagna L
    Eur J Intern Med; 2018 Nov; 57():e11-e12. PubMed ID: 30076088
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
    Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
    Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial thrombosis and anti-PD-1 blockade.
    Boutros C; Scoazec JY; Mateus C; Routier E; Roy S; Robert C
    Eur J Cancer; 2018 Mar; 91():164-166. PubMed ID: 29289455
    [No Abstract]   [Full Text] [Related]  

  • 19. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
    Esfahani K; Buhlaiga N; Thébault P; Lapointe R; Johnson NA; Miller WH
    N Engl J Med; 2019 Jun; 380(24):2375-2376. PubMed ID: 31189042
    [No Abstract]   [Full Text] [Related]  

  • 20. Metastatic Renal Cell Carcinoma Presenting as a Rapidly Enlarging Endotracheal Mass Due to Hyperprogression on Anti-PD1 Immunotherapy.
    Hoshal SG; Wickwire PC; Gandour-Edwards RF; Rajappa P; Cates DJ
    Ear Nose Throat J; 2021 Dec; 100(10_suppl):905S-907S. PubMed ID: 32466731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.